New hope drug enters human testing for Tough-to-Treat blood cancers
NCT ID NCT07114367
Summary
This early-stage trial is testing a new drug called NB02 (posseltinib) in patients with non-Hodgkin's lymphoma that has returned or stopped responding to standard treatments. The main goal is to find the safest dose and understand how the drug behaves in the body. Researchers will enroll 9 patients with specific lymphoma types who have already tried at least two other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA (NHL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Catholic univ of Yeouido St Mary's Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chonnam National University Hwasun Hospital
RECRUITINGHwasun, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ulsan University Hospital
RECRUITINGUlsan, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.